Lincoln Pharmaceuticals · NSE: LINCOLN · BSE: 531633
Q1 FY20 results · Apr–Jun 2019
Lincoln Pharmaceuticals reported revenue from operations of ₹94.59 crore (down 2.1% from Q1 FY19) and net profit of ₹12.16 crore (down 22.0% from Q1 FY19) for Q1 FY20 (Apr–Jun 2019), on a standalone basis.
| Item | Q1 FY20 | Q1 FY19 | YoY | Q4 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 94.59 | 96.63 | −2.1% | 77.46 | +22.1% |
| Other income | 1.58 | 2.24 | −29.5% | (0.59) | Turned profit |
| Total income | 96.17 | 98.87 | −2.7% | 76.87 | +25.1% |
| Profit before tax | 17.00 | 21.95 | −22.6% | 6.96 | +144.2% |
| Net profit for the period | 12.16 | 15.60 | −22.0% | 7.17 | +69.5% |
| EPS, basic (₹) | 6.08 | 7.80 | −22.1% | 3.59 | +69.4% |
| Net margin (%) | 12.9 | 16.1 | 9.3 |
Standalone
- Filed with BSE
- 17 Aug 2019, 12:42 IST
- Board meeting
- 14 Aug 2019
- Period
- 01 Apr 2019 to 30 Jun 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE